The FDA's decision to phase out trans fats has been met with little resistance, due to easy substitutes and consensus on the ingredient's unhealthiness.
Until now, the the Food & Drug Administration has taken a largely hands-off approach to medical apps. For those entrepreneurs who are subject to FDA scrutiny, however, the process can be daunting.